

INTERNATIONAL NORMALISED RATIO MONITORING IN CHILDREN: COMPARING THE ACCURACY OF PORTABLE POINT-OF-CARE MONITORS TO STANDARD OF CARE LABORATORY MONITORING AT RED CROSS WAR MEMORIAL CHILDREN'S HOSPITAL

R Moore¹, A Ferris², S Perkins², A Joachim², Rik De Decker², L Zuhlke²

¹Department of Paediatrics, Red Cross War Memorial Children's Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa ²Division of Paediatric Cardiology, Department of Paediatrics, Red Cross War Memorial Children's Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

INTRODUCTION AND OBJECTIVES

Monitoring the international normalised ratio (INR) is an integral part in management of children on long-term oral anticoagulant therapy. Point-of-care INR monitors such as the Mission[®] PT/INR monitor provide advantages in efficiency and accessibility but have not been evaluated for accuracy in the South African paediatric setting.

We undertook a feasibility study with the aim to evaluate the accuracy of the Mission[®] PT/INR Monitor in comparison to standard laboratory INR measurement, in children presenting for INR testing at a tertiary paediatric facility in Cape Town, South Africa.

MATERIAL & METHODS

Method comparison analysis

The mean INR values for the Mission[®] PT/INR and the laboratory method compared favourably with means of 1.49 (SD 0.73) and 1.39 (SD 0.69) respectively. This represents a slight overestimation of INR values by the Mission[®] PT/INR device. Non-parametric tests showed that this slight overestimation was statistically significant (p-value 0.0012). 92.5 % of INR readings INR results on the POC INR device were within 0.5 units of the laboratory value.

The limit of agreement between the two methods of INR measurement are represented in the Bland-Altman difference plot (**Figure 2**) - this revealed good agreement with mean difference of 0.13 (-0.33; 0.58). Only two values were outside the 95% limits of agreement.





Study design and participants

Children between the ages of 1 year to 17 years were eligible for enrolment. Children under 12 months of age and critically ill children were excluded from enrolment.

Study protocol

Blood samples for INR analysis were obtained consecutively by venepuncture for collection in citrated tubes for measurement on the Sysmex CS-2100i coagulation analyser in the laboratory and then by fingerprick for measurement on the Mission[®] PT/INR device.

Main outcome measures

We compared the accuracy of the Mission[®] PT/INR monitor to the Sysmex CS- 2100i laboratory analyser. We also described secondary variables, including patient demographics and disease profile.



PT Coagulation Monitoring System



Figure 1. The Mission [®] PT/INR monitoring device



RESULTS 1

Thirty-seven (37) participants were enrolled into the study, with forty (40) paired POC INR and laboratory INR values. **Table 1** shows the demographic profile of the study sample.

Table 1. Demographic profile of study sample		Table 2. Disease profile of study sample	
Total number of participants n=37	NI (%)	Total number of participants n=37	N (%)
N (%)	IN (70)	Primary indication for INR testing	
Gender		CARDIAC	7 (19)
Male	23 (62)	Fontan/Glenn circulation	1 (2.7)
Female	14 (38)	Dilated cardiomyopathy	2 (5.4)
Age (vears, months)	()	Prosthetic Valve	3 (8.1)
Youngest	1y 1m	Kawasaki Disease	0
Oldest	, 17y	Primary Pulmonary Hypertension	0
Mean	8y	Other	1 (2.7)
< 5 years	10 (27)	Known cardiac patient?	5 (13.5)
5 - 6 years	5 (13.5)	NON-CARDIAC	30 (81)
>7 years	22 (59.4)	Liver Disease	13 (35.1)
Hospital admission status		Renal Disease	2 (5.4)
Inpatient	14 (38)	Venous Thromboembolism	1 (2.7)
Outpatient	23 (62)	Arterial Thromboembolism	0
Primary Place of Residence		Other	14 (37.8)
Cape Town Metropole	26 (70)	Comorbid illnesses	6 (16.2)
Western Cape (other than Cape Town)	7 (19)	HIV	0
Not from Western Cape	4 (11)	TB	1 (2.7)
Place of Sample Collection		Renal	0
Outpatient clinic	4 (11)	Liver disease	0
Inpatient Wards	15 (40)	Malignancy	1 (2.7)
Ambulatory Medicine department	3 (8)	Haematological	0
Laboratory phlebotomy department	15 (40)	Other	4 (10.8)

Figure 2. Bland-Altman analysis - 95% confidence intervals indicated (grey), bias (black). Markers show the difference between the two methods over the mean

DISCUSSION and CONCLUSIONS

This feasibility study showed that the majority of patients at RCWMCH who required INR testing, did so for screening purposes in non-cardiac disease, with a minority of patients on long-term oral anticoagulation.

The Mission[®] PT/INR has been shown to be accurate in a wide range of readings but follow-up research with a larger study sample is required to provide a power analysis of the accuracy of this device in a tertiary hospital paediatric setting.

This study has shown that this POC INR device may be implemented in an outpatient setting (including peripheral clinics) but that a detailed assessment of the infrastructure and capacity of such settings will be required to allow for appropriate and reliable quality control processes. Before implementation, staff will require training on optimal use and troubleshooting of the device, preferably according to a standard operating procedure, which should address how to proceed if INR readings fall outside of a prescribed range.

Table 2 summarises the disease profile of the participants in the study sample. The minority of participants had their INRs tested for primary cardiac indications (19% vs 81%). Five patients (13.5%) were on anticoagulant therapy including four on warfarin therapy and a fifth on aspirin.

Non-cardiac indications for INR testing predominated in the study sample. The vast majority of these patients had liver disease as the primary indication for INR testing, most of whom had chronic liver disease related to biliary atresia.

ACKNOWLEDGEMENTS

We thank the Paediatric Cardiac Research Unit at RCWMCH for providing stationery and printing facilities, as well as the laboratory and phlebotomy staff at NHLS for their assistance with identifying eligible participants.

Contact information

Dr Ryan Moore - rm84111a@@gmail.com